NGL Fine Chem Ltd
NGL Fine Chem Ltd Q1 FY26 Results & Presentation Highlights: Revenue ₹104.19 Cr, PAT ₹9.24 Cr
Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on NGL Fine Chem Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1FY26 Revenue from operations: ₹104.19 crores - Year-on-year (YoY) revenue growth: 14.80% - Total income Q1FY26: ₹110.54 crores, YoY growth: 14.38% - EBITDA for Q1FY26: ₹10.97 crores, YoY growt EBITDA for the quarter: ₹10.97 crores, up 73.64% YoY, margin 10.53%, up 388 bps YoY (Page 8) - Operating expenses: ₹93.21 crores (Page 8) - Profit after tax (PAT) for the quarter: ₹9.24 crores, up
From NGL Fine Chem Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1FY26 Revenue from operations: ₹104.19 crores
- Year-on-year (YoY) revenue growth: 14.80%
- Total income Q1FY26: ₹110.54 crores, YoY growth: 14.38%
- EBITDA for Q1FY26: ₹10.97 crores, YoY growth: 17.36%
- EBITDA margin improved by 23 bps YoY to 10.53%
- Volume growth primarily drove topline increase in Q1FY26 (Management Commentary, Page 6)
- No explicit quantitative revenue or volume outlook provided
2 more points management made on revenue & sales performance
Profitability & Margins
See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Greenfield expansion at Tarapur with ongoing civil construction; invested ₹119.83 crores till Q1FY26.
- Additional capacities of intermediates completed in subsidiary Macrotech; commercial production started.
- Capacity expansion with sufficient capacity to meet demand for new products in pipeline.
- Estimated capex approximately ₹160 crores to be funded through debt and internal accruals.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
NGL Fine Chem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹145 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What NGL Fine Chem Ltd's management said in earlier quarters
- Q3 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Influx Healthtech Ltd (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key investor presentation takeaways from Influx Healthtech Ltd'
- Shree Ganesh Remedies Ltd (Q1 FY26)
Q1FY26 Revenue from Operations: ₹24.67 crores . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY26 investor presentation — and how it
- Anuh Pharma Ltd (Q1 FY26)
Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. Key investor presentation takeaways from Anuh Pharma
- Bharat Parenterals Ltd (Q1 FY26)
Q1 FY 2026 Revenue from Operations (Consolidated):** ₹116.00 crore, up 25.4% YoY from ₹92.51 crore in Q1 FY 2025 (Page 26). Key investor presentation takeaways
Frequently Asked Questions
What were NGL Fine Chem Ltd Q1 FY26 results?
Q1FY26 Revenue from operations: ₹104.19 crores - Year-on-year (YoY) revenue growth: 14.80% - Total income Q1FY26: ₹110.54 crores, YoY growth: 14.38% - EBITDA for Q1FY26: ₹10.97 crores, YoY growt EBITDA for the quarter: ₹10.97 crores, up 73.64% YoY, margin 10.53%, up 388 bps YoY (Page 8) - Operating expenses: ₹93.21 crores (Page 8) - Profit after tax (PAT) for the quarter: ₹9.24 crores, up
What is NGL Fine Chem Ltd share price analysis?
NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem Ltd planning capital expenditure?
Greenfield expansion at Tarapur with ongoing civil construction; invested ₹119.83 crores till Q1FY26.
Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.